California based City of Hope notched in a grant to grow its phase 1 trial of Mustang Bio’s CAR-T in patients with brain tumors. The grant was valued at $12.8 million grant prepares the team to expand arms that are evaluating different avenues of administration of the IL13Ra2-specific autologous CAR-T cells.
The California Institute for Regenerative Medicine (CIRM) is providing the funds. Maintained by the fresh funding, City of Hope’s Behnam Badie, M.D. and Christine Brown, Ph.D. will expand two arms of the trial that are delivering MB-101 into the cerebrospinal fluid and tumor sites for patients with malignant glioma.
City of Hope notched in the fourth arm to the trial in 2016 to monitor the effect of delivering MB-101 to both the tumor site and cerebrospinal fluid. The additional three arms are assessing delivering the CAR-T cells to either the tumor, the cerebrospinal fluid or a cavity left by eliminating the cancer, also known as intratumoral, intraventricular and intracavitary administration.
The trial has recorded early successes, entailing a complete response in a glioblastoma patient. That patient had three of his five advancing intracranial tumors resected, following the received weekly intracavity infusions of CAR-T cells. The treatment couldn’t halt the new lesions from surfacing, though, encouraging the team to adjust to intraventricular infusions. At the time of the fifth intraventricular infusion, all tumors had reduced by a minimum of 77%.
The patients disease re-appeared after the 16th cycle of treatments, the obvious efficacy of the intraventricular avenue ignited the team to ramp up its interest in its approach. Adding onto the fourth, intratumoral-intraventricular arm and landing of the grant advanced out of this experience.
“This grant will enable the expansion of the phase 1 trial to continue to explore the most effective delivery methods of MB-101,” Mustang CEO Manuel Litchman, M.D., stated in a statement.